CureLab Veterinary
Early Stage
ElenaVet®’s p62 plasmid technology is poised to revolutionize cancer treatment in dogs and cats by upregulating the body's immune system and lowering inflammation.
Overview
Raised: $1,350
Total Commitments ($USD)
Platform
Netcapital
Start Date
12/22/2022
Close Date
02/22/2023
Min. Goal
$10,020
Max. Goal
$1,234,980
Min. Investment
$120
Security Type
Equity - Common
Series
Seed
Funding Type
RegCF
Price Per Share
$30.00
Pre-Money Valuation
$32,653,950
Rolling Commitments ($USD)
Status
Active
Reporting Date
02/03/2023
Days Remaining
19
% of Min. Goal
13%
% of Max. Goal
0%
Likelihood of Max
Avg. Daily Raise
$31
Momentum
Create a free account today to gain access to KingsCrowd analytics.
Location
Dedham, Massachusetts
Industry
Pet Health, Food, and Services
Tech Sector
Medtech
Distribution Model
B2C
Margin
Medium
Capital Intensity
High
CureLab Veterinary, with a valuation of $20 million, is raising funds on Netcapital. CureLab Veterinary product ElenaVet® is an anticancer/anti-inflammatory plasmid therapeutic that is poised to revolutionize cancer treatment in dogs and cats, extending the life of these family members. ElenaVet™ corrects the tumor microenvironment surrounding cancer cells, making it more favorable for anti-cancer immunity. Alex Shneider founded Curelab Veterinary in 2020. The current crowdfunding campaign has a minimum target of $ 10,020 and a maximum target of $1,234,980. The campaign proceeds will be used for compensation for managers, USDA consultant and regulatory, patent licensure and marketing.
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$-450 |
$-1,136 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$0 |
$0 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$0 |
$0 |
|
Short-Term Debt |
$252,544 |
$0 |
|
Long-Term Debt |
$0 |
$0 |
|
Total Liabilities |
$252,544 |
$0 |
Financials as of: 12/22/2022
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.
Ratings 
